Gadolinium-based contrast agent
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
contrast agent
|
| gptkbp:alternativeTo |
iodinated contrast agents
|
| gptkbp:approvedBy |
gptkb:FDA
1988 |
| gptkbp:chemical_structure |
linear
macrocyclic |
| gptkbp:containsElement |
gptkb:gadolinium
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:example |
gptkb:gadobenate_dimeglumine
gptkb:gadobutrol gptkb:gadodiamide gptkb:gadopentetate_dimeglumine gptkb:gadoterate_meglumine gptkb:gadoteridol gptkb:gadoversetamide gadofosveset gadopentetate gadoterate |
| https://www.w3.org/2000/01/rdf-schema#label |
Gadolinium-based contrast agent
|
| gptkbp:mechanismOfAction |
alters magnetic properties of nearby water molecules
|
| gptkbp:notRecommendedFor |
pregnant women
patients with acute kidney injury |
| gptkbp:riskFactor |
gptkb:nephrogenic_systemic_fibrosis
gadolinium retention |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting dizziness headache injection site reaction shortness of breath high blood pressure itching allergic reaction chills rash flushing low blood pressure metallic taste |
| gptkbp:type |
paramagnetic contrast agent
|
| gptkbp:used_in |
magnetic resonance imaging
cardiac imaging liver imaging musculoskeletal imaging magnetic resonance angiography central nervous system imaging |
| gptkbp:usedFor |
enhancing MRI images
|
| gptkbp:bfsParent |
gptkb:GBCA
gptkb:Magnetic_Resonance_Perfusion |
| gptkbp:bfsLayer |
7
|